Skip to main content

olinvyk

Generic: oliceridine

olinvyk: developed by 1 company · 1 FDA decision.

olinvyk evidence translation

What we can confirm

1 FDA record

What it means

Source-backed records connect olinvyk to TRVN; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could olinvyk → TRVN affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
TREVENA INC (TRVN)
management of acute pain severe enough to require an intrave…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 )] , and persist over the course of therapy, reserve opioid analgesics, including OLINVYK, for use in patients for whom alternative tre(TRVN)FDA ↗
NDA210730Type 1 - New Molecular EntityStandardIntravenousSolution

Frequently asked questions

Who is developing olinvyk?

olinvyk is being developed by TREVENA INC.

What is olinvyk's latest FDA decision?

The most recent tracked FDA decision for olinvyk is Approval for 1 INDICATIONS AND USAGE OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 )] , and persist over the course of therapy, reserve opioid analgesics, including OLINVYK, for use in patients for whom alternative tre, dated August 7, 2020.